PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Treatment of drooling with sublingual atropine sulfate in children and adolescents with cerebral palsy.

Abstract To report the effect of sublingual atropine sulfate to treat drooling in children with cerebral palsy by comparing the results of the Drooling Impact Scale in a non-controlled open clinical trial.
PMID
Related Publications

Botulinum toxin effect on salivary flow rate in children with cerebral palsy.

Botox(®) to reduce drooling in a paediatric population with neurological impairments: a Phase I study.

Intraparotid injection of botulinum toxin A as a treatment to control sialorrhea in children with cerebral palsy.

Treatment of sialorrhea in children with cerebral palsy: a double-blind placebo controlled trial.

Effect of botulinum toxin in the treatment of drooling: a controlled clinical trial.

Authors

Mayor MeshTerms
Keywords
Journal Title arquivos de neuro-psiquiatria
Publication Year Start




PMID- 28591387
OWN - NLM
STAT- MEDLINE
DA  - 20170607
DCOM- 20170630
LR  - 20170630
IS  - 1678-4227 (Electronic)
IS  - 0004-282X (Linking)
VI  - 75
IP  - 5
DP  - 2017 May
TI  - Treatment of drooling with sublingual atropine sulfate in children and
      adolescents with cerebral palsy.
PG  - 282-287
LID - S0004-282X2017000500282 [pii]
LID - 10.1590/0004-282X20170033 [doi]
AB  - Objective: To report the effect of sublingual atropine sulfate to treat drooling 
      in children with cerebral palsy by comparing the results of the Drooling Impact
      Scale in a non-controlled open clinical trial. Results: Twenty-five children were
      assessed. The difference in the mean scores of the pre- and post-treatment scales
      reached statistical significance. There was a low frequency of side effects
      compared to studies with other anticholinergics. Conclusion: The use of
      sublingual atropine sulfate seems to be safe and there is a reduction in the
      Drooling Impact Scale score, which suggests efficacy in the treatment of drooling
      in children and adolescents with cerebral palsy. Our results should be replicated
      in randomized, placebo-controlled studies with larger numbers of participants.
FAU - Dias, Bruno L Scofano
AU  - Dias BLS
AD  - Rede SARAH de Hospitais de Reabilitacao; Rio de Janeiro RJ, Brasil.
FAU - Fernandes, Alexandre R
AU  - Fernandes AR
AD  - Universidade Federal Fluminense; Niteroi RJ, Brasil.
FAU - Maia, Heber de S Filho
AU  - Maia HS Filho
AD  - Universidade Federal Fluminense; Niteroi RJ, Brasil.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Brazil
TA  - Arq Neuropsiquiatr
JT  - Arquivos de neuro-psiquiatria
JID - 0125444
RN  - 0 (Muscarinic Antagonists)
RN  - 7C0697DR9I (Atropine)
SB  - IM
MH  - Administration, Sublingual
MH  - Adolescent
MH  - Atropine/*administration & dosage/adverse effects
MH  - Cerebral Palsy/*complications
MH  - Child
MH  - Child, Preschool
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Male
MH  - Muscarinic Antagonists/*administration & dosage/adverse effects
MH  - Severity of Illness Index
MH  - Sialorrhea/*drug therapy/etiology
MH  - Treatment Outcome
EDAT- 2017/06/08 06:00
MHDA- 2017/07/01 06:00
CRDT- 2017/06/08 06:00
PHST- 2016/08/12 [received]
PHST- 2016/12/20 [accepted]
AID - S0004-282X2017000500282 [pii]
AID - 10.1590/0004-282X20170033 [doi]
PST - ppublish
SO  - Arq Neuropsiquiatr. 2017 May;75(5):282-287. doi: 10.1590/0004-282X20170033.